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Abstract: The widespread use of antiretroviral therapy (ART) has entirely changed the 
management of human immunodeficiency virus (HIV) infection and dramatically reduced the 
rates of opportunistic infections (OI). However, OI continue to cause significant morbidity 
and mortality in both developed countries, where presentation with advanced HIV infection is 
common, and also in developing countries where ART is less widely available. Evidence to direct 
OI guidelines is partly limited by the fact that many large-scale studies date from the pre-ART era 
and more recent studies are sometimes poorly powered due to the falling rates of OI. Treatment of 
OI is now known to be as much about antimicrobials as about immune reconstitution with ART, 
and recent studies help guide the timing of initiation of ART in different infections. OI have also 
become complicated by the immune reconstitution inflammatory syndrome phenomenon which 
may occur once successful immune recovery begins. Trimethoprim-sulfamethoxazole has long 
been one of the most important antibiotics in the treatment and prevention of OI and remains 
paramount. It has a broad spectrum of activity against Pneumocystis jiroveci, toxoplasmosis, 
and bacterial infections and has an important role to play in preventing life-threatening OI. New 
advances in treating OI are coming from a variety of quarters: in cytomegalovirus eye disease, 
the use of oral rather than intravenous drugs is changing the face of therapy; in cryptococcal 
meningitis, improved drug formulations and combination therapy is improving clearance rates 
and reducing drug toxicities; and in gut disease, the possibility of rapid immune restitution with 
ART is replacing the need for antimicrobials against cryptosporidia and microsporidia.
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Introduction
Advances in the treatment of human immunodeficiency virus (HIV) with effective 
antiretroviral therapy (ART) in the last 20 years have dramatically changed the face 
of HIV infection. This has led to a sharp reduction in both opportunistic infections 
(OI) and death rates. In spite of this, OI continue to cause significant morbidity and 
mortality in patients with HIV all around the world. In developed countries, late 
presentation of HIV remains a considerable problem, with over 20% of patients in 
the UK presenting with CD4 , 200 cells/µL and therefore being at risk of OI.1 Other 
patients have a suboptimal response to ART due to poor adherence to therapy, drug 
toxicities, and extensively drug-resistant HIV virus, so remain immunosuppressed in 
spite of treatment. In developing countries, lack of access to ART and medical facili-
ties makes OI a common occurrence.
A critical review of antimicrobial treatment for OI is necessary because while 
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available for the treatment of specific OI is ever increasing 
and in some cases the incidence of drug resistance forces a 
change in treatment guidance. Moreover, the use of ART in 
addition to, and in some occasions instead of, antimicrobials 
has altered both the drugs used and their treatment duration. 
Thus, a review of antimicrobial treatment of OI now that 
the use of ART is widely established brings together new 
knowledge from the ART-era as well as using many studies 
performed before the widespread use of ART.
However, it is a limitation of this review that many of 
the large-scale randomized control studies quoted were 
carried out prior to the widespread availability of effective 
ART and a consequence of the decline in incidence of OI 
is that many centers no longer see a large enough number 
of specific infections to carry out well-powered controlled 
studies. This appraisal does not seek to be a comprehensive 
review of the treatment of all OI, but more a discussion on 
the data that guides everyday practice in treating the major-
ity of infective admissions in HIV-infected individuals in 
the developed world.
Methods
This review was carried out by performing a PubMed 
database search on the various topics OI covers. It included 
studies from both the pre- and the post-ART era and this 
is highlighted in the text where relevant. Due to the recent 
nature of the disease, all studies that relate specifically to 
HIV date from the mid-1980s onwards.
The role of ART
The majority of patients who present with OI are not already 
taking ART, therefore initiation of ART and the specific 
timing of ART initiation will play a major role in the 
management of the acute OI. For certain OI where there is 
no specific antimicrobial treatment, ART may be the only 
treatment available; in other infections, patients will be sta-
bilized with antimicrobials before starting ART. Recent data 
regarding the specific timing of introducing ART generally 
favors early initiation2,3 but this must always be balanced 
with the problem of overlapping drug toxicities, drug–drug 
interactions and the potential for an immune reconstitution 
inflammatory syndrome (IRIS) to complicate the manage-
ment of the acute OI.
The data that guides the introduction of ART during an 
acute OI comes from several studies conducted in different 
parts of the word. The AIDS Clinical Trial Group (ACTG) car-
ried out a large randomized trial where patients either started 
ART “early” ie, within 14 days of   starting OI   treatment, or 
“late” ie, after completion of OI treatment. Importantly, 
patients with tuberculosis (TB) were excluded from the 
study, but they demonstrated both fewer deaths and less 
AIDS progression in the early initiation arm.3 The SAPIT 
study in Durban, South Africa looked specifically at TB and 
randomized patients into “integrated treatment” and “sequen-
tial treatment” arms depending on when ART was initiated. 
They found that the integrated treatment arm, which started 
ART within the first 3 months of TB treatment, had a 56% 
relative reduction in mortality compared to those who started 
after TB treatment completion.2 A further study performed 
in Cambodia, the CAMELIA trial, found a similar benefit in 
early use of ART in conjunction with TB treatment.4 There 
have been worries that starting ART early increases the risk 
of IRIS, however, a review of the data from the ACTG study 
has not shown that early initiation of ART is associated with a 
greater risk of IRIS. They did however find that in patients in 
advanced immunosuppression, risk factors for IRIS included: 
fungal infection, lower CD4+ T-cell counts and higher HIV 
RNA levels at baseline, and higher CD4+ T-cell counts and 
lower HIV RNA levels on treatment.5
Overview of antimicrobial therapy 
in HIV
Probably the most widely used antibiotic worldwide in the 
HIV-infected population is trimethoprim-sulfamethoxazole 
(TMP-SMX) which is used as prophylaxis for   Pneumocystis 
jiroveci pneumonia (PCP) in patients with CD4 , 200 cells/µL. 
Its additional prophylactic activity against toxoplasmosis and 
its antibacterial activity against a number of important bacte-
rial pathogens including Salmonella spp. and Streptococcus 
pneumoniae has led to a general decrease in the number of 
life-threatening bacterial infections occurring in patients 
with advanced HIV infection, particularly in resource-poor 
settings, although the rates have not decreased to those seen 
in the HIV-negative population. TMP-SMX is a relatively 
broad-spectrum antibiotic that has activity against many other 
common respiratory, skin, and bowel pathogens. Despite 
the widespread use of TMP-SMX worldwide, resistance to 
PCP is not commonly reported and most cases of PCP and 
toxoplasmosis respond to first-line agents.6,7
Respiratory infections
Respiratory symptoms may be caused by a number of differ-
ent OI, particularly given that HIV-associated T and B cell 
dysfunction increases the incidence of respiratory infec-
tions at all CD4 counts. PCP remains the most common and 
clinically important severe OI, although bacterial infections, HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Mycobacterium tuberculosis and other fungal and viral infec-
tions should always be considered. In general, a clinician is 
able to rapidly risk assess a patient depending on the present-
ing symptoms and the degree of immunosuppression. This 
is important, as it is almost always necessary to commence 
antimicrobial therapy before laboratory confirmation or 
isolation of the suspected pathogen. A notable exception to 
this rule may be mycobacterial infections, which is beyond 
the scope of this review article.
Pneumocystis jiroveci pneumonia
Pneumocystis jiroveci pneumonia (PCP) is caused by the 
fungus Pneumocystis jiroveci, a ubiquitous organism that 
usually causes primary infection in early childhood. Current 
evidence is in favor of disease in the immunosuppressed 
being caused largely by reinfection with the fungus although 
reactivation of latent infection may also occur.8 PCP often 
has an insidious onset and patients classically present with 
dry cough and shortness of breath on exertion.
Any consideration of antimicrobials for the treatment of 
PCP must take several factors into consideration:
1.  the severity of disease, as determined by hypoxemia 
(ie, PaO2 , 9.3 kPa or SpO2 , 92% on room air)
2.  the need for intravenous versus oral medication
3.  the tolerability of the regime and the impact of drug 
toxicities
4.  prior treatment with PCP prophylaxis.
First-line treatment for severe PCP
Most clinicians agree that first-line treatment for severe disease 
remains with high-dose intravenous TMP-SMX for 21 days. It 
has an efficacy of around 90% in mild disease and 70% in severe 
disease. This has been compared extensively against other 
regimes including pentamidine, primaquine and clindamycin, 
atovaquone, and dapsone. The only other drug that has similar 
efficacy in severe PCP is intravenous pentamidine.
The initial evidence for the treatment of PCP came from a 
number of studies performed in the pre-ART era.6 The largest 
of these studies, published in 1992, enrolled 163 patients and 
compared high dose intravenous TMP-SMX (120 mg/kg/day) 
with intravenous pentamidine (4 mg/kg/day). In general, these 
two agents compared equally in terms of efficacy and toxicity.9 
In other comparative studies, side effects in both treatment 
arms were nearly universal and failure to complete treatment 
or the need to switch regimen was often as high as 40%. The 
most common side effects of TMP-SMX were rash and ane-
mia, and of pentamidine were nephrotoxicity, hypotension, 
and hypoglycemia.
Supportive care for the side effects of TMP-SMX may 
be effective, and persisting by “treating through” the mild 
side effects can limit the need for a treatment change.10,11 
This is not the case with pentamidine where nephrotoxicity 
normally necessitates switching treatment. For this reason, 
TMP-SMX has remained the first-line treatment for PCP in 
OI guidelines from both the British HIV Association, which 
are due to be published in 2011, and the Infectious Diseases 
Society of America (IDSA).12 Ultimately, the decision to 
treat with one drug or another is often made on an individual 
patient basis, depending on side effect profile. It should be 
added that there have been no recent well-powered studies 
comparing the two agents head-to-head. Prior treatment 
with TMP-SMX prophylaxis is not a contra-indication 
to its use at treatment dose as PCP infection is normally 
a result of poor adherence or drug absorption rather than 
drug resistance.
Patients with severe PCP, as defined by PaO2 , 9.3 kPa 
or SpO2 , 92% on room air, should receive corticosteroids, 
and a survival benefit has been clearly demonstrated in a 
number of studies.13,14 The preferred regimen of prednisolone 
is 40 mg twice daily for days 1–5, 40 mg daily for days 5–10, 
and 20 mg daily for days 11–21. If intravenous steroids are 
required, then intravenous methylprednisolone given at 75% 
of the prednisolone doses is used.15
Second-line treatment for PCP
Robust data exists regarding second-line treatment 
regimes and treatment for mild to moderately severe PCP 
and there are a number of different reasonable treatment 
options that may be used according to an individual clini-
cian’s   preference. A study by Safrin et al compared three 
oral regimens in nonsevere PCP: TMP-SMX, dapsone-
trimethoprim, and clindamycin-primaquine. 181 patients 
were randomized to one of the three treatment arms and 
the study concluded that there were no statistically signifi-
cant differences between the groups in terms of the rates 
of therapeutic failure, drug toxicities, or completion of 
the treatment course.10 Other studies have shown similar 
results, including a double-blind randomized multicenter 
comparison of TMP-SMX with clindamycin-primaquine 
which reported a treatment success rate of 79% and 76%, 
respectively. Atovaquone has also been used in the treat-
ment of PCP, and is reported to be less efficacious but better 
tolerated when compared to   TMP-SMX.16 Ultimately, when 
many regimes have been shown to be effective, treatment 
choice is more arbitrary and may depend on local protocols 
and patient factors.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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For nonsevere PCP and when treatment can be given orally 
and even on an out-patient basis, the preferred   regimens are: 
oral TMP-SMX or oral clindamycin-primaquine. Patients who 
improve on intravenous therapy may be switched to an oral 
alternative if they are clinically improved. For those who fail 
to respond in spite of 5–7 days of first-line treatment, there 
is little to choose in terms of efficacy between second-line 
agents and choice is normally governed by individual patient 
factors such as tolerability and severity of PCP.17
Bacterial respiratory infections
Bacterial respiratory infections include pneumonia, tracheitis, 
and bronchitis. The causative organisms are broadly similar 
to those in non-HIV infected individuals. Streptococcus 
pneumoniae, Haemophilus influenzae, Mycoplasma pneu-
monia, and Chlamydia pneumoniae are the most commonly 
isolated bacteria. S. pneumoniae predominates, accounting 
for up to 40% of all bacterial pneumonia. Other less common 
causes of pneumonia (ie, Chlamydia psittaci, Legionella, 
and Staphlycoccus aureus) should also be considered and 
tested for with serological tests, urinary antigen testing, and 
microbiological culture where possible.
The risk of invasive pneumococcal disease (IPD) is also 
greater in HIV-infected patients than the general population.18 
This may be partially explained by a predisposition to pneu-
mococcal nasopharyngeal colonization. In a longitudinal 
cohort of 260 mother-infant pairs in Zambia, half of who 
were HIV-seropositive, HIV infection was associated with 
an increased risk of colonization, particularly with pediatric 
serotypes.19 The treatment of IPD in the HIV setting needs to 
be prompt and aggressive as it carries a higher mortality risk 
in HIV-infected individuals and a higher risk of recurrence.20 
As with non-HIV infected individuals, high dose penicillin 
forms the cornerstone of treatment.
Bacterial tracheitis and recurrent bronchitis, often associ-
ated with bronchiectasis, are also frequent in HIV-infected 
individuals. The isolated bacterial pathogens are similar 
to those causing pneumonia and include S. pneumoniae, 
H. influenzae, S. aureus, and P . aeruginosa.
Empiric treatment is generally dependent upon the 
clinical presentation and the degree of immunosuppression. 
In patients presenting with typical symptoms of bacterial 
pneumonia plus focal consolidation on chest radiograph, 
the initial antibiotic regimen will be directed at the most 
common community-acquired pathogens and will normally 
include a penicillin-based antibiotic such as amoxicillin or 
co-amoxiclav with a macrolide, ie, clarithromycin or eryth-
romycin, as first-line treatment.
The decision to treat as an outpatient or inpatient 
will depend on the clinical status and the reliability of 
the   individual. In general, the approach to treatment of 
community-acquired pneumonia is similar to that in the 
HIV-seronegative patient and there is very little specific 
evidence to guide the treatment in HIV-infected individuals. 
Clearly, as with other patients, treatment is based on history 
such as recent hospital admission, travel history and country 
of residence, taking into account data on local antimicrobial 
susceptibilities, concurrent immunomodulators, and the 
degree of immunosuppression. Clinicians should also take 
into account existent antibiotic prophylaxis (eg, TMP-SMX 
for PCP prophylaxis) when making decisions regarding 
administering empiric treatment for intercurrent bacterial 
infections. Naturally, the choice of antimicrobials will also 
depend on whether there are any features present to suggest a 
nonbacterial cause, ie, PCP, tuberculosis, or viral pneumoni-
tis, when more specific treatment is indicated.
Central nervous system disease
Disease of the central nervous system (CNS) is a common 
occurrence in HIV and may present as a space occupying lesion, 
meningoencephalitis, or with an AIDS-dementia   complex. 
The mode of presentation, in conjunction with brain imaging 
and examination of the cerebral spinal fluid (CSF) helps to 
establish the correct diagnosis. Here we discuss the common 
manifestations of nonmycobacterial CNS infection – cerebral 
toxoplasmosis and cryptococcal meningitis.
Cerebral toxoplasmosis
Toxoplasmosis usually manifests with multiple brain 
abscesses and is the most common cause of cerebral mass 
lesions in HIV-infected individuals worldwide. Primary 
infection often occurs early in life and symptomatic infec-
tion occurs in immunocompromised individuals due to 
reactivation of latent toxoplasma cysts. The most common 
clinical manifestation of toxoplasmosis in AIDS is a limited 
encephalitis associated with headache, fever, and focal neu-
rology, although a more diffuse encephalitis with confusion 
and altered consciousness may also occur.
Due to the impracticality of obtaining brain tissue from 
most patients, treatment for toxoplasmosis is generally 
undertaken on the basis of positive toxoplasma serology, a 
compatible history, and mass lesions on brain imaging. An 
objective clinical response with improvement in brain imag-
ing at 2 weeks is taken to be sufficient evidence for diagnosis, 
and first-line therapy is effective in approximately 90% of 
patients with cerebral toxoplasmosis.21HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Treatment phase
First-line treatment for cerebral toxoplasmosis is a 6-week 
course of pyrimethamine, sulphadiazine, and folinic acid. 
Pyrimethamine is given as an initial 200 mg loading dose, 
followed by weight-based therapy (50 mg/day if weight 
less than 60 kg or 75 mg/day if weight more than 60 kg). 
Pyrimethamine is only available in oral preparation and 
in the unconscious patient must be given via a nasogastric 
tube but is poorly absorbed, necessitating the initial loading 
dose. Sulphadiazine (15 mg/kg, four times daily) may be 
given either orally or intravenously, although the oral route 
is preferred due to its good bioavailability. Folinic acid 
(leucovorin) is given to prevent the hematological toxicities 
of pyrimethamine.
The evidence for the stated regime is derived from two 
randomized double-blind studies comparing pyrimethamine-
sulphadiazine with pyrimethamine-clindamycin. Dannemann 
et al (1992) and Katlama et al (1996) both reported equivalent 
treatment success although there seemed to be a survival 
benefit in the pyrimethamine-sulphadiazine arm.7,22 When 
the two studies were combined in a Cochrane review, mor-
tality was comparable,23 suggesting that both regimes are 
a reasonable option. Thus, for those who cannot tolerate 
sulphadiazine, substitution with clindamycin (300 mg, four 
times daily) is an acceptable alternative, especially since it 
is reported to be better tolerated than sulphadiazine.
Other regimes that are used for treatment include atova-
quone (1500 mg, twice daily) with either sulphadiazine or 
pyrimethamine or therapy with TMP-SMX alone. Evidence 
suggests that these regimens are effective, but the studies lack 
sufficient patient numbers to be well powered and there is 
less clinical experience with these regimens.24 An observa-
tional study of 83 patients in the French West Indies had an 
85% treatment success rate with TMP-SMX alone, although 
they reported a relapse rate of 30% and a multicenter Italian 
study with 40 patients in the TMP-SMX arm showed similar 
findings compared to the standard first-line therapy.25,26 This 
is promising due to the fact that TMP-SMX is widely avail-
able and cheap compared to other regimes, but the high rate 
of relapse is worrying and makes its use as a first-line agent 
unfavorable. Other sulphadiazine-sparing regimes that have 
been used with success for the treatment of toxoplasmosis 
include clarithromycin, azithromycin, doxycycline, and 
dapsone combined with pyrimethamine-folinic acid, but the 
evidence is limited and currently they do not perform as well 
as either of the first or second line regimes.
The routine use of corticosteroids in toxoplasmosis is 
discouraged as without a tissue/microbiological diagnosis, 
they cloud the picture in what is effectively a therapeutic drug 
trial, since cerebral inflammation associated with primary 
CNS lymphoma and Mycobacterium tuberculosis will also 
respond to corticosteroids.
Maintenance therapy
After the initial 6-week treatment phase, secondary prophy-
laxis or maintenance therapy is continued. This is lifelong or 
until there is immune recovery, ie, CD4 . 200 cells/µL for 
more than 6 months. There are few specific trials to guide 
secondary prophylaxis however, but evidence from studies 
looking at prophylaxis for PCP have shown that TMP-SMX 
at 480–960 mg/day is highly effective27 and that while dap-
sone (50 mg/day) plus pyrimethamine (50 mg weekly) is 
effective,28 it should only be used in those who are intoler-
ant to sulphadiazine due to the dual effect of TMP-SMX in 
prophylaxis against PCP pneumonia.
Cryptococcosis
Cryptococcosis is the most common systemic fungal infection 
in HIV-infected individuals and is associated with profound 
immunosuppression, occurring usually at CD4 , 50 cells/µL 
and is universally fatal if untreated. It presents as a subacute 
meningitis or meningoencephalitis and is complicated by 
raised intracranial pressures in up to 75% of patients. In dis-
seminated cryptococcosis, CNS symptoms may be absent, 
but pulmonary infection may occur with diffuse pulmonary 
infiltrates, nodules on chest radiograph, and symptoms 
including fever, cough, and dyspnea.
Induction treatment
Treatment is divided into two phases, induction and main-
tenance. Across the developed world, most would agree 
that gold-standard induction therapy combines intravenous 
liposomal amphotericin B (4 mg/kg/day) and flucytosine 
(100 mg/kg/day) for at least 2 weeks. However, this treat-
ment combination has many side effects, with amphotericin 
causing renal toxicity and flucytosine causing bone marrow 
suppression. If this regimen is not tolerated, and also in 
resource poor settings, where these drugs may not be avail-
able, good results have also been shown with oral fluconazole 
(400 mg/day) both alone and with flucystosine.29,30 There is 
also evidence to suggest that fluconazole may increase the 
fungicidal effect of flucytosine, enabling lower doses of flucy-
tosine to be administered and improving tolerability, although 
this has yet to be translated into current practice.31
Amphotericin B has historically been the drug of choice 
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the normal dose (generally 0.7 mg/kg/day). There is much 
evidence now to support the use of liposomal amphotericin B, 
which has high rates of CNS penetration and can therefore be 
used at lower doses. This leads to better rates of CSF steril-
ization, significantly reduces the incidence of renal toxicity, 
and improves drug tolerability.32–34 This has now become the 
standard of care in much of the developed world, although 
may be hard to source in resource-poor countries where HIV 
infection is prevalent.
Initial data for the use of flucytosine with amphotericin B 
came from a study in the pre-HIV era. This showed that the 
addition of flucytosine was associated with fewer treatment 
failures or relapses than amphotericin alone in cryptococcal 
meningitis.35 Furthermore, Van de Horst et al in 1997 demon-
strated that the addition of flucytosine to amphotericin does 
not improve early outcome but reduces the risk of relapse by 
improving rates of CSF sterilization.36 A more recent study 
of HIV-associated cryptococcal meningitis in a resource-poor 
setting has added weight to the evidence that the addition of 
flucytosine speeds the sterilization of CSF. Nussbaum et al 
compared fluconazole monotherapy with fluconazole plus 
flucytosine and found faster CSF sterilization and a reduced 
early and late mortality in the combination arm.37
Not all studies are easily compared however, as some of 
the earlier studies used lower doses of amphotericin B and 
were performed before the widespread availability of lipo-
somal preparation. In addition, some studies that compared 
amphotericin and fluconazole used a lower dose of flucon-
azole (200 mg/day) than is standard practice currently, so the 
difference needs interpreting with caution. There is no robust 
data to guide treatment if either of the first-line agents cannot 
be tolerated due to severe side effects. Clinicians may choose 
to simply omit the flucytosine and continue with amphotericin 
alone, or treat with flucytosine and fluconazole in combina-
tion if the amphotericin must be discontinued. Generally, 
oral fluconazole is a good alternative when resources are not 
available for the gold standard treatment as it may be given 
with or without flucytosine.
Regarding the newer azoles (ie, voriconazole or posicon-
azole), there are no controlled studies to support their use and 
given their high cost, they are normally only used anecdotally 
for cases when fluconazole cannot be tolerated or has failed. 
There is no role for the echinocandins (ie, caspofungin, 
micafungin) in the treatment or prophylaxis of cryptococ-
cal meningitis as the organism is inherently resistant to the 
entire class of drugs.
The timing of initiation of ART in cryptococcal disease 
remains an area of controversy. A prospective Zimbabwean 
study of 54 patients compared early initiation of ART 
(within 72 hours) with delayed ART (after 10 weeks). It 
was terminated early due to a markedly increased mortal-
ity in the early initiation arm.38 However, the fact that they 
did not compare any time points in between 72 hours and 
10 weeks is a major drawback as this would be when most 
clinicians would choose to initiate therapy. In addition, the 
study used fluconazole monotherapy (800 mg), which would 
not normally be the treatment of choice due to slower fungal 
CSF clearance. It also had a median follow-up time of only 
27 days, which limits its robustness. It is clear that further 
information is required before being able to judge the opti-
mum time for ART initiation in this context, however current 
guidance from the IDSA is to start between 2 and 10 weeks 
after initiation of an amphotericin-based regime.39
Maintenance therapy
Maintenance treatment follows directly on from the induc-
tion phase and is normally started after the 2-week treatment 
phase provided there has been a good clinical response, 
although some clinicians prefer to repeat the CSF exami-
nation and only switch to maintenance therapy once CSF 
culture is cryptococcus negative. This is a realistic option in 
developed countries where most of these patients are treated 
as inpatients and the resources are available for repeated CSF 
examinations, but in resource-poor countries, repeated lum-
bar punctures and CSF culture is often not feasible. In guiding 
maintenance therapy, a number of studies have shown that 
oral fluconazole (400 mg/day) has been shown to be superior 
at preventing relapses than placebo, oral itraconazole, and 
weekly amphotericin B injections.40,41 Maintenance treat-
ment is continued for a total of 10 weeks before patients are 
stepped down to secondary prophylaxis (fluconazole 200 mg 
daily), which is continued lifelong or until sustained immune 
reconstitution occurs.
Gastrointestinal disease
The most common symptoms of gastrointestinal (GI) disease 
in HIV are weight loss and diarrhea. However, patients may 
present with a variety of symptoms including dysphagia, 
nausea, abdominal pain, and anorexia. The GI tract may be 
affected by a wide range of pathogens, from the types of bac-
terial gastroenteritides that are common in non HIV-infected 
individuals to opportunistic fungi, viruses, and parasites. Now 
that ART use is widespread, the incidence of many of these 
opportunistic gut infections has diminished   enormously; 
however, in late presenters and those unresponsive to ART, 
they are still observed to cause chronic infection.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Acute bacterial gastroenteritis
As with bacterial respiratory infection, bacterial gastroenteri-
tis is many times more common in HIV-infected individuals 
at all CD4 counts, but is particularly associated with older age 
and lower CD4 counts. The most commonly isolated organ-
isms are non-typhi Salmonella (especially Typhimurium and 
Enteritidis), Shigella and Campylobacter, and Clostridium 
difficile has also been described in one large US cohort as 
the most common cause of bacterial diarrhea in hospital-
ized patients with HIV .42,43 Clinical presentation can be one 
of three: 1) a self-limiting gastroenteritis; 2) a more severe 
and prolonged gastroenteritis associated with bloody diar-
rhea, fever, and weight loss; or 3) septicemia with or without 
a preceding GI illness. Salmonella, in particular, can cause a 
recurrent septicemia in immunosuppressed patients, which 
is prone to relapse and may be due to the T cell dysfunction 
seen at all CD4 counts.44–46
Clearly the mode of presentation determines the type and 
route of treatment given. Acute bacterial gastroenteritis in a 
patient with CD . 200 cells/µL does not necessarily need 
antimicrobial treatment and may be self-limiting. However, 
in the context of immunosuppression, treatment is generally 
recommended.
Salmonella gastroenteritis in an immune competent 
individual does not normally require treatment, and there 
are no trials in the HIV population to guide the manage-
ment of patients with CD4 . 200 cells/µL. However, in 
an individual on ART with a well-preserved CD4 count, 
many clinicians would agree that it might be reasonable to 
withhold antibiotics. On the other hand, some clinicians 
would view the risk of bacteremia and relapse to be suf-
ficiently high, even in immune-reconstituted HIV-infected 
individuals to warrant treatment. Treatment should always 
be guided by in vitro sensitivity testing, but first-line 
empiric treatment with an oral fluoroquinolone is usual, 
ie,   ciprofloxacin 500 mg twice daily. There is however, 
growing resistance to ciprofloxacin worldwide in both 
Salmonella sp. and Campylobacter sp.47,48 and alternatives 
include third generation cephalosporins, azithromycin, or 
TMP-SMX.49 It is therefore important that local resistance 
patterns and protocols guide the choice of first-line therapy. 
In the case of bacteremic patients, some clinicians advocate 
the addition of a second agent and this may be advised until 
strain sensitivities are known, but there is no current evi-
dence to suggest that dual therapy rather than single agent 
therapy is associated with a better outcome.
The length of treatment for salmonellosis is poorly 
defined, but 5–7 days is generally adequate. Bacteremic 
patients are often treated for 2 weeks but there is little 
evidence on which to base this. Studies from the pre-ART 
era and from Africa have reported recurrent bacteremia in 
as many as 45%–47%.50,51 This has been illustrated to be 
due to recrudescence rather than re-infection and raises 
the   question of whether long-term suppressive therapy is 
indicated in those with CD4 , 200 cells/µL.52 However, in 
more recent years when it is rare not to be able to construct 
an effective ART regime, the risk of recurrence has not 
been shown to be reduced by long-term fluoroquinolone 
prophylaxis.48
Campylobacteriosis, as with salmonellosis, does not 
necessitate treatment if mild and in an immune compe-
tent host. However, in the immunocompromised and in 
those with persisting disease, antimicrobials are indicated. 
  Fluoroquinolones have historically been the mainstay of 
treatment, but with emerging resistance patterns, macrolides 
such as azithromycin are being used effectively as first-line 
treatment.53
Shigella gastroenteritis may be mild and self-limiting, but 
there is good evidence that the use of antibiotics decreases the 
duration of symptoms and the risk of recurrence.54   Treatment 
with a fluoroquinolone for 5 days is effective, as are TMP-
SMX or azithromycin. Specific treatment is guided by clinical 
response and local sensitivity patterns.
Treatment of C. difficile in HIV follows the same guide-
lines as for non-HIV infected individuals. The crux is to 
stop any antimicrobials predisposing to the infection and 
then to treat with metronidazole 400 mg three times daily or 
vancomycin 125 mg four times daily. A prospective study 
of C. difficile diarrhea has shown that HIV infection is not 
associated with worse outcomes or poorer response to stan-
dard treatment.55
Cryptosporidiosis and microsporidiosis
Cryptosporidia and microsporidia are protozoan parasites that 
cause an acute or subacute profuse, non-bloody, watery diar-
rhea, and are a common cause of chronic diarrhea in advanced 
HIV infection.56 Additional symptoms include nausea, vomit-
ing, abdominal cramping, fever, and malabsorption. If the 
biliary tract is infected, a sclerosing cholangitis may arise, 
particularly in prolonged disease. The incidence of both dis-
eases has declined dramatically with the introduction of ART. 
The most important treatment for both infections is the resto-
ration of immune function and symptoms completely resolve 
without additional treatment once CD4 . 100 cells/µL.57,58 
ART is therefore the absolute cornerstone in the treatment 
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Treatment of cryptosporidia
There is little convincing evidence for the efficacy of antimi-
crobial therapy in the treatment of cryptosporidium. Multiple 
agents (nitazoxanide, paromomycin, spiramycin) have been 
shown in small randomized controlled trials to have some 
positive effect, but none have been shown to have a lasting 
effect without ART.59 Paromomycin is a nonabsorbable 
aminoglycoside, which is effective against cryptosporidia 
in animal models but there have been mixed data in HIV-
infected adults and studies are limited by small numbers.60–62 
A recent meta-analysis of its efficacy has shown no evidence 
for its use, although a small study of eleven patients showed 
a reduction in diarrheal frequency and oocyst shedding when 
given in combination with azithromycin.63,64
Nitazoxanide, a broad spectrum antiparasitic agent, has 
been approved for use in immunocompetent individuals but 
has not been shown to be superior to placebo in the severely 
immunocompromised in whom cryptosporidium is most 
problematic.65 There is little evidence to support its use and 
its widespread availability is questionable. In the absence of 
effective antimicrobials, supportive therapy with rehydration 
and electrolyte replacement is vital. Antimotility agents such 
as loperamide can provide symptomatic benefit.
Treatment of microsporidia
Microsporidia are ubiquitous organisms that are likely to 
be zoonotic and waterborne in origin. The most common 
microsporidia infecting the human gut are Enterocytozoon 
bieneusi and Encephalitozoon intestinalis. As with cryp-
tosporidiosis, immune restoration with ART is the most 
important therapeutic consideration and in the context of 
profuse diarrhea, absorption of ART may need to be verified 
with therapeutic drug level monitoring.
There is no specific antimicrobial agent directed against 
E. bieneusi, although a single study showed that it may 
respond to oral fumagillin (20 mg, three times daily for 
14 days).66 However, fumagillin is not licensed for systemic 
therapy in the US or UK. Nitazoxanide, albendazole, and itra-
conazole have also been studied. Of these agents, albendazole 
(400 mg, twice daily for 21 days) has been shown to improve 
stool frequency and microsporidia clearance, although patient 
numbers in each study were small.67,68
Candidiasis
Candidal infection of the oropharynx is common and is a 
recognized surrogate marker of immunosuppression.69 Oral 
candida, diagnosed clinically by identification of the char-
acteristic white plaques in the buccal mucosa or   surface of 
the tongue, may be asymptomatic or symptomatic. Candidal 
infection of the esophagus, by contrast, is rarely asymptom-
atic and presents with fever, odynophagia, and retrosternal 
discomfort. It is unusual without coexisting oral candida 
and most physicians would treat empirically based on symp-
toms and the presence of oral candidiasis, only proceeding 
to endoscopy if symptoms do not rapidly improve with 
  treatment. The most important differentials to rule out are 
herpes simplex virus or cytomegalovirus (CMV) esophagitis, 
which endoscopy with biopsy or brushings is able to do.
Treatment of oral candida is effective with both topical 
agents, ie, nystatin suspension or amphotericin lozenges 
or systemic treatment with an oral azole. However, topi-
cal treatment has been shown to be associated with slower 
clearance of the yeast and a higher rate of relapse.70 Thus, 
unless there is a specific contraindication to the use of an 
azole, most clinicians would favor systemic treatment in the 
immunocompromised patient.
Regarding choice of azole, fluconazole, itraconazole, 
and ketoconazole are the most commonly used systemic 
treatments and they all have activity against oropharyngeal 
candida.71–74 A number of well-designed studies have shown 
that fluconazole and oral suspension itraconazole are superior 
to ketoconazole and tablet formulation itraconazole.71,74,75 
This is related to the properties of the itraconazole and 
ketoconazole capsules, which require gastric acid in order 
to facilitate absorption. Advanced HIV is often associated 
with achlorhydria, which impairs the efficacy of these capsule 
agents. The use of oral solution itraconazole bypasses this 
mechanism and has been shown to have a better bioavailabil-
ity than the capsule formulation.75 A very large prospective 
Italian study compared fluconazole with itraconazole for 
the treatment of candida esophagitis and found similar cure 
rates but a better short-term response with fluconazole.76 
Fluconazole is therefore usually the first-line agent of choice 
at a dose of 50–100 mg/day for 7–14 days, depending on 
clinical response.
Fluconazole-refractory candida should be tested for flu-
conazole resistance and a number of other antifungal drugs, 
such as the newer azoles and the echinocandins, may be 
considered for treatment in these cases.77 The echinocandins, 
such as caspofungin and micafungin, have been shown to be 
comparable to fluconazole for the treatment of esophageal 
candidiasis although some may be associated with a higher 
relapse rate.78–80 Direct comparison between studies is 
however limited by the differing doses of fluconazole used 
in the various studies. However, a small study that looked 
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  esophageal candidiasis found that it was associated with 
a clinical response in 79% of patients that had a reduced 
susceptibility to fluconazole, making it a very good second-
line option.81 The newer azoles, such as voriconazole and 
posiconazole, have also been shown to have activity against 
fluconazole-resistant strains.82,83 There is no role for primary 
or secondary prophylaxis in candidiasis due to the rapid 
emergence of resistant strains.84
In summary, fluconazole remains the usual first-line agent 
for both oral and esophageal canididasis, although topical 
agents may also be used with good effect in oral candidiasis. 
In the event of fluconazole-refractory disease, second-line 
treatment is successful with either an echinocandin or one 
of the newer azole agents.
Multisystem or disseminated 
infections
Atypical mycobacteria
The most clinically important atypical mycobacterial 
infection is Mycobacterium avium intracellulare complex 
(MAC), which causes disseminated disease and presents 
with systemic features of infection in individuals with 
CD4 , 50 cells/µL. Commonly infected sites include the 
lungs, bone marrow, liver, and lymph nodes with mycobac-
teria often grown from blood culture and isolated from these 
normally sterile sites. Historically, treatment of MAC has 
been difficult and prolonged, but with the concomitant use of 
ART, treatment outcomes are much improved. Again, many 
studies predate the ART era, which has dramatically reduced 
the incidence of MAC as well as shifting its clinical presen-
tation to include more focal disease and a well-recognized 
IRIS phenomenon.
Macrolide therapy, in addition to some of the traditional 
antituberculous drugs, forms the cornerstone of MAC treat-
ment and randomized clinical trials with macrolide containing 
regimes have better outcomes than nonmacrolide containing 
regimens.56 A number of studies have compared clarithromycin 
with azithromycin and shown consistently that clarithromycin 
is associated with more rapid resolution of bacteremia.85,86 
Azithromycin (500–600 mg daily) however, is better tolerated 
than clarithromycin and is a legitimate second-line option 
if drug–drug interactions or intolerance preclude the use of 
clarithromycin.87 Macrolide monotherapy is associated with 
drug resistance;88 therefore a second and/or third agent is 
required. Most clinicians would agree that ethambutol is the 
second agent of choice as more than any other drug, it has 
been shown to be associated with reduced incidence of drug 
resistance and clinical relapse.60–62 A study that compared 
ethambutol to rifabutin as the second agent with   clarithromycin 
showed no difference in bacteremia resolution rates but higher 
rates of relapse in the rifabutin arm.89
ART forms a vital component of the treatment of atypi-
cal mycobacterial infection. In light of this and on the basis 
of current evidence,2 normal practice is to start ART within 
2 weeks of antimycobacterial therapy and if this is the case, 
it can be argued that a third agent is not required. In patients 
for whom it is not possible to construct an effective ART 
regime, or who have had a poor immune response to treat-
ment, the addition of a third antimycobacterial agent may be 
warranted and this is usually rifabutin. Rifabutin has been 
shown to protect against drug-resistance, which may become 
more of a concern if an individual will need prolonged treat-
ment, and in some studies has been associated with improved 
survival.89,90 However, the use of rifabutin complicates the 
construction of an ART regime due to its potent induction 
of the CYP 450 liver enzyme and many clinicians opt for 
dual therapy in conjunction with ART, omitting rifabutin. 
Evidence from the pre-ART era suggests that the addition of 
rifabutin improved microbiological clearance and survival 
rates;89,90 however, in the context of effective ART, rifabutin 
may no longer be a necessary component of MAC treatment. 
Other agents such as clofazamine and ciprofloxacin have also 
been compared, but have poorer clinical outcomes.91,92
Treatment failure is defined as lack of clinical response 
and persistent mycobacteremia after 4–8 weeks of treatment. 
MAC isolates should be tested for drug susceptibility to 
clarithromycin and azithromycin, however the predicative 
value of susceptibility testing for ethambutol and rifabutin 
has not been confirmed.93 Susceptibility testing should guide 
the construction of a new regime and using the same prin-
ciples as treating drug-resistant Mycobacterium tuberculosis, 
should include at least two new drugs from different classes 
to which the isolate should be susceptible. These include 
rifabutin (if not previously used), a quinolone (ciprofloxacin, 
levofloxacin, or moxifloxacin), linezolid, or amikacin.94 Other 
third-line agents such as prothionamide or cycloserine have 
only been used anecdotally and their efficacy is unknown.
In cases of refractory MAC, where immune reconstitution 
has not occurred and combination antimycobacterial therapy 
has not been successful, there is a limited amount of emerg-
ing evidence to support the use of immune modulators. One 
small case series has reported that low-dose dexamethasone 
reduces symptoms such as fever and weight loss, but this 
has yet to be substantiated fully.95 Another small case series 
reported an increase in monocyte activity in the blood after 
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  factor (gCSF) with antimycobacterial therapy, but this was not 
associated with a significant decrease in mycobacteremia.96 
Interferon gamma has also shown some mixed results. It 
has been shown to increase the phagocytosis of MAC by 
blood monocytes in an HIV-infected patient with advanced 
MAC,97 but although there are a few case reports of clinical 
and radiological improvement in non HIV-infected individu-
als, the case reports in HIV-infected individuals report little 
sustained effect.98
There are no randomized studies to guide the duration 
of MAC treatment. However, most evidence suggests that 
treatment may be discontinued once immune recovery 
has been achieved. In practice, this constitutes a clinical 
response to MAC treatment for at least 3 months and both 
HIV virological suppression and immune recovery with a 
CD4 . 100 cells/µL for more than 3 months. If these criteria 
have not been achieved then the best evidence suggests that 
treatment should be lifelong and overall prognosis is poor.
CMV infection
CMV disease is caused by reactivation of the latent virus that 
is usually acquired in childhood. It occurs in those with CD4 
counts below 100 cells/µL, but predominates in individu-
als with CD4 , 50 cells/µL. The widespread use of ART 
has dramatically decreased its incidence and has led to the 
recognition of CMV IRIS as a distinct presentation during 
immune recovery. It is a multisystem infection causing end-
organ disease in the eye, gut, lung, and CNS.
CMV eye disease
Retinitis is the most common clinical manifestation of CMV 
disease. It usually begins unilaterally, but without immune 
reconstitution or systemic treatment, bilateral disease ensues 
almost universally. Diagnosis is made clinically with dilated 
fundoscopy by an experienced ophthalmologist. Treatment 
is indicated for all new cases, progression of existing lesions 
and reactivation of old lesions and seeks to limit progression 
of the retinitis and to reduce the risk of sight loss due to both 
macular involvement and retinal detachment.
Treatment can either be given locally or systemically. 
Local treatment via intraocular implants or injections has 
the advantage of being able to deliver high doses of drug 
directly to the affected area and avoids the toxic side effects 
of systemic treatment; systemic treatment however provides 
necessary prophylaxis to the contralateral eye and most HIV 
physicians would consider it to be best practice unless there 
are specific contraindications to its use. Drug therapy may 
be individualized to some extent according to the location 
and severity of disease, the degree of immune suppression, 
the likelihood of overlapping drug toxicities, and the ability 
of a patient to adhere to treatment.
Treatment is divided into an induction period of 2–4 weeks 
and a maintenance phase of treatment at lower doses which 
is continued until immune reconstitution occurs.
Induction treatment
Antivirals such as oral valganciclovir (900 mg twice daily), 
intravenous ganciclovir (5 mg/kg twice daily), foscarnet 
(90 mg/kg twice daily), and cidofovir (5 mg/kg) have all been   
shown to be effective and are all reasonable options in the 
treatment of CMV disease.99,100 However, data from the Val-
ganciclovir Study Group sways opinion towards the use of oral 
valganciclovir, a prodrug of ganciclovir with excellent oral bio-
availability, which has been demonstrated to maintain patients 
in remission for longer than intravenous ganciclovir and is 
therefore normally used as first-line treatment.101 Regarding 
local therapy, the use of a ganciclovir implant has been shown 
to be superior to treatment with intravenous ganciclovir alone 
and for this reason, if an individual presents with immediately 
sight-threatening lesions, ie, disease in zone 1 of the retina, 
many experts would advise local treatment in addition to 
systemic therapy.102 Other local treatments include intravitreal 
injections with ganciclovir, foscarnet, and fomivirsen but there 
is less robust evidence to support their use.103–105
Maintenance treatment
Due to the very high risk of relapse and progression, main-
tenance therapy or secondary prophylaxis is continued after 
the induction phase. Several regimes have been shown to be 
effective including oral valganciclovir 900 mg daily, intra-
venous ganciclovir 5 mg/kg daily (or 6 mg/kg for 5 days a 
week), intravenous foscarnet 90 mg/kg daily (or 120 mg/kg 
for 5 days a week), and intravenous cidofovir 5 mg/kg fort-
nightly. Clearly, given the strong evidence supporting the use 
of oral valganciclovir, its ease of use compared to the other 
regimes makes it the most favorable option.
Maintenance treatment is continued until immune 
reconstitution occurs and ART should be started as soon as 
is feasible. There is no evidence to suggest that concurrent 
treatment with ART and anti-CMV therapy is associated 
with worse outcomes. In the absence of immune restitution, 
CMV relapse over time is inevitable.101
Treatment of reactivation or progression
Relapse may occur due to inadequate intraocular drug lev-
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attributable to poor intraocular penetration of systemically 
administered drugs and is best treated with a local ganciclovir 
implant. This has been shown to control the eye disease for up 
to 6–8 months, by which time the implant will need replace-
ment and immune recovery may well have occurred.108,109
Relapse that occurs early on in maintenance therapy 
and which does not affect zones 1 and 2 may be treated by 
re-induction with the same drug, ie, oral valganciclovir, 
and this is normally effective at controlling the retinitis, 
though normally for shorter amounts of time. Changing to 
a different drug does not produce superior outcomes unless 
drug resistance is suspected, while combination therapy is 
associated with a longer mean time to relapse but can be 
poorly tolerated due to drug toxicities.110
Significant drug resistance does occur in long-term 
treatment. Resistance rates are typically less than 10% 
in the first 3 months of treatment but rise to 25%–30% 
by 9 months of therapy.111–113 Later relapse is often due 
to drug resistance, which is conferred through the CMV 
UL97 and UL54 genes. If low-level resistance is detected, 
treatment with intraocular ganciclovir implant may be 
effective due to the higher concentration of drug admin-
istered. If high-level resistance occurs, then a treatment 
change is required.
extra-ocular CMV disease
The diagnosis of CMV disease at any site outside the eye 
should prompt urgent referral for ophthalmologic examina-
tion to rule out concomitant CMV eye disease, which if 
undiagnosed can cause irreversible loss of sight. As with 
CMV retinitis, ART is vital to the long-term suppression of 
CMV and there is no data to suggest early ART initiation 
has any detrimental effect on acute CMV disease.
Gastrointestinal disease caused by CMV can affect any 
part of the gut, but colitis and esophagitis are the more 
common manifestations. Diagnosis is made by endoscopic 
examination, revealing characteristic ulceration of the gut 
mucosa, and histologic confirmation on biopsy which shows 
the classic intracytoplasmic “owl’s eye” inclusions. Culture 
of CMV from biopsy samples has been shown to be unreliable 
as a diagnostic tool as immunosuppressed individuals may 
shed the virus asymptomatically without evidence of ulcer-
ative disease. Intravenous ganciclovir and foscarnet are both 
effective treatments and normal treatment is for 14–28 days. 
If symptoms are not severe enough to alter absorption, oral 
valganciclovir may also be used effectively. Maintenance 
therapy is not recommended routinely for gut disease except 
in cases of relapse.
CMV disease of the nervous system accounts for less 
than 1% of clinical CMV disease but may present as an 
AIDS-dementia complex, a ventriculo-encephalitis, or a 
polyradiculitis. Diagnosis is made on the basis of a positive 
CSF CMV DNA polymerase chain reaction (PCR) and by 
characteristic patterns on gadolinium-enhanced magnetic 
resonance imaging. Treatment for neurologic disease has 
been somewhat extrapolated from the extensive studies 
carried out in CMV eye disease and there have been no 
prospective controlled studies for CNS CMV disease itself. 
Treatment with ganciclovir, foscarnet, cidofovir, and val-
ganciclovir all decrease CSF CMV titers, but are not very 
efficient in stabilizing neurologic disease. A small study 
from the pre-ART era looked at combination treatment 
with ganciclovir and foscarnet, but found poor results.114 It 
is likely that prompt treatment, early ART and combination 
therapy all play a role, but drug toxicity often limits the 
duration of combination therapy and optimum treatment 
is not known.
CMV pneumonitis is uncommon and presents with fever, 
dry cough, exertional dyspnea, and hypoxemia. Chest imag-
ing typically shows bilateral interstitial infiltrates, but may 
show nodules, adenopathy, and even cavitation. The major 
challenge is in distinguishing between asymptomatic CMV 
viral shedding in the respiratory secretions and active CMV 
lung disease. A positive CMV culture from respiratory 
samples such as bronchoalveolar lavage has a low posi-
tive predictive value but a high negative predictive value. 
A biopsy sample, however, is more sensitive. Generally, 
a compatible clinical syndrome, radiology, and positive 
CMV biopsy in the absence of a more likely co-pathogen 
are required before treatment of CMV is warranted. Again, 
treatment with intravenous ganciclovir, foscarnet, or oral 
valganciclovir is effective.
Finally, there is controversy surrounding the use of CMV 
viremia detected by PCR as a diagnostic tool for CMV 
disease.115,116 No prospective studies currently exist look-
ing at the levels of CMV viremia and future risk of CMV 
disease or the preventative value of preemptive treatment. 
However, studies are on-going, and until robust data shows 
a clinical benefit, treatment of CMV viremia in the absence 
of   end-organ disease is not currently recommended.
Conclusion
The field of HIV medicine has grown with a remarkable 
speed and energy over the last 20 years. The advances that 
have been made regarding ART have radically changed the 
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professionals concerned with their care. In contrast to the 
huge changes in drug treatment for HIV, advances in the 
treatment of the common OI have been relatively meager. 
However, optimal treatment of OI remains an important 
issue as patients continue to present with advanced HIV 
infection. While the main advance in recent years has been 
the use of early ART as an adjunct to antimicrobial therapy, 
there is ongoing controversy regarding the specific tim-
ing of ART initiation during an acute OI. In general, “the 
earlier the better” is the message from studies addressing 
the question, but there remains some uncertainty with TB, 
where TB-IRIS causes considerable morbidity, and with 
cryptococcal meningitis where early ART has been shown 
to increase mortality.
Treatment of OI continues to be plagued by three main 
issues. The first is that the side effect profile of many drugs 
often limits their use. The second is that the gold standard 
treatment for many OI relies on a period of intravenous 
therapy or a costly oral alternative and these are not an 
option for many in resource-poor countries due to financial 
and logistical constraints. Finally, antimicrobial resistance 
continues to emerge, especially in parts of the world that rely 
heavily on fluoroquinolones for the management of bacterial 
infections. So far, in spite of its prolific use in prophylaxis 
there is little evidence of widespread TMP-SMX-resistant 
PCP, but this would have detrimental consequences, espe-
cially in resource-poor countries. In conclusion, there remains 
an urgent need for continued research into the treatment of OI 
with the aim of shortening intravenous courses and improv-
ing oral therapies and finding new regimes with improved 
drug toxicity profiles.
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